SANDY, UT (October 1, 2004) – In an unprecedented announcement in the history of network marketing, 4Life announced today that 4Life Transfer Factor products as immune modulators have been approved for use in hospitals and clinics in the Russian Federation. The results of ten separate clinical trials and two experimental studies on 4Life Transfer Factor products were combined in a Methodological Document that was approved by the Ministry of Health, which now allows doctors to recommend 4Life Transfer Factor Classic and 4Life Transfer Factor Plus Advanced products to their patients.
First Dietary Supplement Approved for Use by Doctors and Hospitals in Russia
Commenting on this remarkable achievement, David Lisonbee, CEO of 4Life stated, “To my knowledge, this is the first time in the history of this industry that a network marketing company or any other dietary supplement company has had one of its dietary supplements approved for use in hospitals in Russia. The Russian Ministry of Health is the equivalent of the Food and Drug Administration in the United States. Doctors and scientists from Russia have been working jointly with scientists from 4Life for several years to arrive at this accomplishment. This approval establishes a new role of dietary supplements in the Russian health care system.”
Remarkable Response from Russian Academy of Medical Sciences
In another sector of research of 4Life Transfer Factor, Dr. Kisielevsky of the Russian Academy of Medical Sciences stated, “The 4Life sample [Transfer Factor Advanced Formula] activated NK (natural killer) cell activity more than the Interleukin-2 (IL2) drug we used as the standard. This discovery has attracted the attention of The International Scientific and Technical Center (ISTC) of Russia.”
Scientists from Several Countries Join Forces for Additional Clinical Studies of Transfer Factor
The ISTC of Russia is a member of a joint international project with other health agencies of Japan, Europe and the US. The objective of the international project is to combine efforts in finding improved immunotherapies. Following the discoveries from the NK cell testing, the scientists of 4Life have been invited to join the project. 4Life Transfer Factor as an immune modulator will be further researched in this international forum. The cost of the studies will be paid by the ISTC.
Speaking of this benchmark achievement, Dr. Calvin McCausland, VP of Research of 4Life, and Dr. Emma Oganova, 4Life/Eurasia President, jointly expressed that because of the acceptance by such a reputable organization and doctors from Russia and other major countries, 4Life Transfer Factor will gain wider acceptance in the professional and private sectors as a superior immune system enhancing product. The worldwide ramifications to this acceptance are just beginning.